VXRT — Vaxart, Inc.
—
OTC ·
Health Care ·
Biotechnology ·
CIK 72444 ·
Last close
$0.55
Market Cap
$132.16M
52W High
$0.79
52W Low
$0.49
ADV30
325,671
Next earnings
2026-05-07
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 39,227,000 | — | 5,173,000 | 5,179,000 | 180,055,000 | 50,746,000 | 85,938,000 |
| Dec 2025 | 104,239,000 | — | 55,423,000 | 55,045,000 | 186,079,000 | 53,814,000 | 98,281,000 |
| Sep 2025 | 72,413,000 | — | -7,811,000 | -8,141,000 | 208,988,000 | 16,880,000 | 182,232,000 |
| Jun 2025 | 39,730,000 | — | -14,603,000 | -14,986,000 | 164,085,000 | 20,111,000 | 131,207,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$7,714,000
Investing CF
$16,632,000
Financing CF
$4,239,000
CapEx
$-292,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.24
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-460,195,000
Inventory
—
Receivables
$51,345,000
ST Investments
$9,993,000
EBIT TTM
$19,626,000
Pretax Income TTM
$16,803,000
Interest Exp TTM
$2,823,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$255,608,992
EBITDA
$45,640,000
Free Cash Flow
$-32,711,124
Enterprise Value
$83,617,880
Total Cash
$61,022,000
Total Debt
$12,202,000
Shares Out
242,044,838
Trailing EPS
$0.16
Book Value
$0.39
ROE
53.1%
ROA
14.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 237,258,000 | 18,074,000 | 16,327,000 | 186,079,000 | 98,281,000 | — | 7,714,000 |
| Dec 2024 | 28,700,000 | -66,293,000 | -66,948,000 | 166,389,000 | 107,464,000 | — | -44,764,000 |
| Dec 2023 | 7,379,000 | -83,347,000 | -82,465,000 | 91,830,000 | 34,025,000 | — | -70,453,000 |
| Dec 2022 | 107,000 | -110,333,000 | -107,758,000 | 153,847,000 | 43,250,000 | — | -94,779,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.03
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ENGN | enGene Therapeutics Inc. | $127.28M | $1.90 | — |
| AGEN | AGENUS INC | $139.50M | $3.35 | — |
| CRDL | Cardiol Therapeutics Inc. | $116.42M | $1.01 | — |
| MOLN | MOLECULAR PARTNERS AG | $150.94M | $4.02 | — |
| IPHYF | Innate Pharma SA | $154.94M | $1.65 | — |
News headlines (Yahoo Finance, 1h cache)
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
2026-07-06 20:01 · Yahoo
Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements
2026-07-01 20:00 · Yahoo
Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
2026-06-26 12:00 · Yahoo
Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
2026-06-25 12:00 · Yahoo
Vaxart’s Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting
2026-06-16 12:00 · Yahoo
Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum
2026-06-15 12:00 · Yahoo
Vaxart to Participate in BTIG Infectious Disease Day 2026
2026-06-09 12:00 · Yahoo
Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
2026-06-08 12:00 · Yahoo
Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders
2026-06-01 12:18 · Yahoo
Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders
2026-05-19 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.